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Background: The search for modiﬁer genes to explain inconsistencies in cystic ﬁbrosis (CF) genotype–phenotype relationships has yielded mixed
results. In a previous cross-sectional study from our centre the clinical effect (as described by FEV1, BMI z-score, admitted days and NIH score) of
single nucleotide polymorphisms (SNPs) of four cytokine genes (IL-8, TNF-α, IL-1β and IL-10) was examined in 158 children with CF. No association
between cytokine genotype and any biological outcome measure was found. In this present study a cross-sectional and longitudinal examination of this
relationship was undertaken to test the hypothesis that pro-inﬂammatory SNPs would affect longitudinal changes in CF lung disease.
Methods: Using the cohort examined in our earlier study we performed both longitudinal and cross-sectional data analyses examining the
relationship between SNPs (TNF-α, IL-8, IL-10 and IL-1β) and clinical outcome measurements. In the ﬁrst part of this current study, lung function
data (annual decline of FEV1 percent predicted) was compared with the cytokine genotype over a 13 year period. In the second part of this current
study multiple regression was used to assess associations between clinical outcomes (best FEV1 percent predicted and BMI at the age of 10 years)
and alleles of cytokine genes, adjusting for gender, CF genotype and lung infection status.
Results: A total of 152 patients with CF were analysed in the longitudinal study and data from 130 patients at the age of 10 years were analysed in the
cross-sectional study. There was evidence for an association between pro-inﬂammatory SNPs of the IL-8, IL-10 and IL-1β genes and more severe lung
disease. Multiple regression of the longitudinal data with a total of 10,956 lung function measurements showed an additional annual decline of the
percentage predicted FEV1 of −1.15 (IL-8, p b 0.001), −0.24 (IL-10, p = 0.049) and −0.41 (IL-1β, p b 0.001) for patients with any of the pro-
inﬂammatory alleles. None of the cross-sectional data showed a signiﬁcant association between the cytokine genotypes and the clinical outcomes.
Conclusion: Pro-inﬂammatory alleles of three cytokine genotypes, IL-8, IL-10 and IL-1β, appear to be associated with slightly more severe lung
disease in patients with CF over a 13 year period. Further studies are required to exclude inﬂuence of confounders on the severity of lung disease.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Modiﬁer genes; Single nucleotide polymorphism; Cytokine genotype1. Introduction
Lung disease is the most common cause of illness and death
in patients with cystic fibrosis (CF), and is characterized by☆ Data presented in this manuscript has been presented in poster form at the
Australian Cystic Fibrosis conference in August 2013 and the North American
Cystic Fibrosis conference in October 2013.
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http://dx.doi.org/10.1016/j.jcf.2014.04.007
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B,.V. Apersistent lung infection and progressive lung damage. Previous
studies have suggested that a significant degree of lung damage in
CF is caused by the host inflammatory response to infection,
rather than the infection itself. While cystic fibrosis (CF) is a
monogenic disease caused by mutations in the CF transmem-
brane conductance regulator (CFTR) gene, the severity of lung
disease cannot be predicted on the basis of the CF gene mutation
present in any individual patient. The clinical phenotype of CF
lung disease varies considerably amongst patients with the same
genotype [1]. This has led to the hypothesis that other “modifier”ll rights reserved.
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been supported by observations that monozygous CF twins have
significantly more concordant levels of chloride transport than
dizygous CF twins suggesting that environmental influences do
not account entirely for the discrepancy [2]. The search for
modifier genes is important to provide new insight into disease
pathogenesis.
Classes of modifiers previously investigated include inflam-
matory and anti-inflammatory mediators, molecules involved
in CF trafficking, alternative ion channels, antioxidants and
mediators of airway reactivity [3]. There is increasing evidence
for genetic variants of the profibrotic cytokine TGF-β influencing
severity of CF lung disease [4–7]. These cross-sectional studies,
with cohorts ranging between 171 and 808 patients, showed a
more rapid deterioration in the FEV1 of patients with the TGF-β1
codon 10 high producer genotype. In addition, polymorphisms
of the mannose binding lectin (MBL2) gene, which result in
lower MBL expression and increase bacterial colonization [8],
are associated with early mortality in CF [9], earlier onset of
Pseudomonas aeruginosa (PA) infection and more rapid decline
of pulmonary function [10]. Hull and Thomson found an
association between the TNF-α −308a allele and a lower FEV1
% predicted and weight z score, whereas Yarden et al. found that
the −308g allele tended to be associated with a more severe CF
phenotype, although not significantly [11,12]. In one of the
largest examinations of the relationships between modifying
genes and lung disease severity in CF, Beucher et al. examined
the association of lung disease with the variant AGER −429T/C
which codes for RAGE, a pro-inflammatory protein in 967 CF
patients who were homozygous for p.Phe508del. The functional
promoter AGER −429C variant was found to be associated with
increased RAGE expression and poorer lung function.
Infection with PA is associated with airway inflammation
characterised by a marked neutrophil influx, and high levels of
the pro-inflammatory cytokines interleukin-1 beta (IL-1β),
interleukin-6 (IL-6), interleukin-8 (IL-8), and tumour necrosis
factor alpha (TNF-α) [13]. Variations in the output of these
factors due to gene variations may help explain the genotype–
phenotype variations seen in CF lung disease. Gene modifier50
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Graph 1. Lung function vs. age for TNF-α.studies may also help identify targets for the development of
anti-inflammatory treatments [14].
In previous research from the Royal Children's Hospital,
Melbourne (RCH) a cohort of 158 children with CF was studied
between May and November 2002 (unpublished data). In each
patient a cheek swab for DNA for genotyping of inflammatory
genes was obtained to compare the various SNPs with different
phenotypes. Data collected included growth parameters (includ-
ing BMI z-scores), recent pulmonary function test results, sputum
isolates and number of inpatient days for treatment of lung
disease in the previous year.
Based on the knowledge from previous findings [15], the
candidate inflammatory genes selected for investigation in this
study were IL-8, TNF-α, IL-1β (pro-inflammatory) and IL-10
(anti-inflammatory).
The aim of the 2002 cross-sectional study was to determine if
any SNPs of the cytokines had any effect on the CF phenotype
with particular influence to parameters of lung health. No
association was found between cytokine genotypes and FEV1,
BMI z-score, admitted days or NIH score (including unpublished
data). Limitations of this study included the analysis of
cross-sectional rather than longitudinal data and the small patient
number.50
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evidence after studying change in lung function longitudinally
suggesting that associations between variations in SNPs and a
decline in lung function do exist. Beucher et al. demonstrated
that AGER (advanced glycation endproducts receptor), which
codes for the pro-inflammatory protein (RAGE), could be a
modifier gene of lung disease severity in CF [16]. They
observed an increase in lung disease severity (mean difference
FEV1 percent-predicted: −4.4 ± 1.9%, p = 0.02) in CF patients
carrying at least one AGER −429C allele. Levy et al.
investigated whether variations in the family of genes affecting
the biology of interleukin-1 (IL-1) which impacts acquisition
and maintenance of P. aeruginosa infection in animal models
of chronic infection could account for the heterogeneity of
pulmonary disease severity seen in CF. 58 SNPs in the IL-1
gene cluster from 808 CF patients homozygous for Δ508 were
studied. SNPs rs1143634 and rs1143639 in the IL-1β gene
were found to be associated with lung disease severity [17].
MBL2 and TGF-β1 may have a role in progression of CF
lung disease and there is some evidence that MBL2 deficiency
in combination with TGF-β1 codon 10 C allele is associated
with both early onset of infections and rapid deterioration of
lung function. Also, TNF-α and IL-6 are major predictors for
rapid weight loss in adult CF patients [14]. Recently Li et al. in
a cohort of 815 patients with CF examined whether SLC26A9,
SLC9A3 and SLC6A14 genes known to contribute to meconium
ileus in CF were pleiotropic for other early affecting CF
co-morbidities. SLC26A9 was found to be pleiotropic for
meconium ileus and pancreatic damage, SLC9A3 for meconi-
um ileus and lung disease and SLC6A14 for both meconium
ileus and lung disease at age of first P. aeruginosa infection
[18].
Most studies have investigated associations between modi-
fiers and severity of pulmonary phenotype. For the majority of
candidate genes, however, results have been conflicting. No
longitudinal research has extended past a period of more than
5 years. It is possible that by examining longitudinal data over a
more extended period, genetic factors modifying the phenotype
of CF would be identified [19].We hypothesized that decline in lung function (FEV1 percent
predicted) over 13 years would be associated with proinflam-
matory single nucleotide polymorphisms (SNPs) of the selected
genes. We further hypothesized an association between inflam-
matory gene polymorphisms and lung disease severity and body
mass index (BMI), when adjusted for gender, CF genotype, and
presence or absence of lung infections at the age of 10 years.
2. Methods
2.1. Patients
The 2002 cohort served as the patient population for this 2012
study thus providing longitudinal and cross-sectional data for 158
patients. In 2002 all patients attended the CF Unit at The Royal
Children's Hospital in Melbourne. In this follow-up study
patients were currently patients at several different centres
encompassing paediatric or adult CF services within Australia.
In order to compare lung disease severity between patients
with different cytokine genotypes we collected data from the
patients between the age of 6 and 19 years. A total of 6 patients
were excluded from the longitudinal study because there was
no record of any lung function measures being performed.
Patients who had received lung transplants subsequent to 2002,
7 in total, were included only up to the last data point obtained
immediately pre-transplant. No patients in the study cohort
received a lung transplant before the age of 19 years. From the
original 2002 cohort 9 patients had died before the age of 19, all
from CF related lung diseases. All data up to the time of death
was included.
Regarding the cross-sectional study, data from 130 patients
of the 2002 cohort were examined at their tenth year of life. We
excluded 28 patients as they had no lung function measurement
at the age of 10 years.
The study was approved by the Human Research Ethics
Committee of The Royal Children's Hospital Melbourne.
2.2. Data collection
The first part of this study is a longitudinal, retrospective
epidemiological study. All 158 patients had already been
genotyped for pro-inflammatory cytokine gene polymorphisms.
Children with CFwere genotyped for each of the four SNPs (IL-8,
TNF-α, IL-1β and IL-10) in 2002. Lung function (including
forced expiratory volume in one second, FEV1) was measured
using a Jaeger MasterScope spirometer (Jaeger, Würzburg,
Germany) and had been performed under ATS criteria [20]. All
lung function tests between the age of 6 and 19 years old were
obtained from source documents. In addition, lung function
reports provided measurements of height and weight at the time of
each lung function test. We used the data conversion program
from Global Lungs Initiative (GLI 2012) to convert the lung
function measurements to all-age predicted values.
The cross-sectional data were obtained from lung function
and microbiological reports. In order to compare disease
severity between the patients, all clinical data were examined
during the age of 9.5–10.5. During this age we use the best lung
Table 1
Primer Sequences.
Gene SNP Primer Primer sequence (5′–3′)
Bi-allelic ARMS primers
TNF-α −308 A/G TNF-α-F GCATCCTGTCTGGAAGTTAG
TNF-α-F-G ATAGGTTTTGAGGGGCATGG
TNF-α-R-A GAGGCTGAACCCCGTCCT
TNF-α-R TCTGGAGGAAGCGGTAGTG
IL-1β −511 C/T IL-1β-f TGAGCTTATCTCCCAGGGTT
IL-1β-F-T CAATTGACAGAGAGCTCCT
IL-1β-R-C TGCTGTTCTCTGCCTCG
IL-1β-R GGGTACAATGAAGGGCCA
IL-10 −1082 A/G IL-10-F CAATCTGGCTCCCCTTACC
IL-10-F-G TACTAAGGCTTCTTTGGGAG
IL-10-R-A ACCTATCCCTACTTAAAAT
IL-10-R ACTGAGAATTTGGTTTCCTCA
ARMS primers
IL-8 −251 A/T IL8-F TGCCCTTCACTCTGTTAAC
IL 8-R-A CCACAATTTGGTGAATTATCAAT
IL8-R-T CCACAATTTGGTGAATTATCAAA
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ing height and weight. To calculate the body mass index (BMI),
we used the Children's BMI-percentile-for-age Calculator from
the USDA/ARS Children's Nutrition Research Center [21].
Sputum/broncho-alveolar lavage (BAL) results for P.
aeruginosa (PA), clonal PA strain (based on genotyping of the
organism, previously reported in our clinic and now called the
AUST-01) and Burkholderia cepacia (BC) were obtained from
microbiological reports [13]. Children were recorded as being
positive if these organisms had been isolated on at least one
occasion.
For all the patients the CF genotype was recorded in 2002.
2.3. Genotyping
DNA lysate preparations were made using a simple NaOH
method. Genotyping for each of the polymorphisms was
performed using a fluorescent bi-allelic ARMS PCR assay for
TNF-α, IL-1β, and IL-10 and a fluorescent ARMSPCR assay for
IL8, analysed by melt-curve analysis on a real-time I-Cycler PCR
machine. Cyber green fluorescence was incorporated into the
PCR product to allow detection. The bi-allelic ARMS assay
requires 4 primers. Primer details are shown in Table 1. In the
assays, each polymorphism generates a certain sized PCR
product, which melts at a specific temperature. The presence of
a peak at the specific temperature indicates the identification of
the polymorphism. The presence of one peak indicates homozy-
gosity for that polymorphism; the presence of two peaks indicates
heterozygosity for the polymorphism.
The polymorphic allele for TNF-α (“A”) is located at position
−308 in the promoter region (rs1800629). The polymorphic
allele for IL-1β (“T”) is at position −511 in the promoter region
(rs16944). The IL-8 polymorphic allele (“A”) is located at
position −251 in the promoter region (rs4073). The IL-10
polymorphic allele (“A”) is located at position −1082 in the
promoter region (rs1800896).
2.4. Statistical analysis
All calculations were performed in Stata 12.0. Multiple
regression was used to assess associations between clinical
outcomes (FEV1 percent predicted and age) and alleles of
cytokine genes for a 13 year period. The cross-sectional data was
analysed with multiple regression to assess associations between
clinical outcome measures and cytokine genes, adjusting for
gender, CF genotype and PA, clonal PA strain and BC status.
3. Results
3.1. Longitudinal data
A total of 10,956 measurements of FEV1 within a 13-year
period of 152 patients (53.3% female) were reviewed and
compared with the cytokine genotype for each of the four
cytokines (Table 2). (See Table 1.)
All cytokine gene analyses compared patients with “any”
pro-inflammatory allele (homozygous or heterozygous) versusthose with “no” pro-inflammatory allele, as previously reported
(Table 3) [2–4].
Results of multiple regression tests for dichotomised
cytokine genotypes are included in Table 4. There was
evidence for those with one or more pro-inflammatory alleles
of the IL8, IL-10 and IL-1β genes to have an additional annual
decline in the FEV1 % predicted (resp. −1.15, −0.24 and
−0.41) than those with the non-inflammatory cytokine
genotype (p b 0.05) (Figs. 1–4). Taking into account that the
analysis for TNF-α with the interaction with age was not
significant (0.07, p =0.51), we found a significant lesser decline
in lung function without looking at the interaction (1.05, p =
0.005). Comparing the results of the patients who died between
the age of 6 and 19 years (n = 9) with the rest of the cohort
(n = 143) a lesser decline in lung function in the deceased
patients is found with any of the pro-inflammatory alleles for
IL-10 and IL-1β. Patients with a pro-inflammatory allele of IL-8
show an additional decline of the FEV1 % predicted without
using the interaction with age (p = 0.016) (Graphs 5–11).
In our cohort there were 81 patients (49.4% females) with a
total of 5818 lung function measurements who were homozy-
gous for the ΔF508 gene. These patients had a mean FEV1 %
predicted of 68.32 (range of 13–139). Multiple regression
analysis showed a significant additional yearly decline of the
FEV1 % predicted for patients with any pro-inflammatory allele
of TNF-α, IL-10 and IL-1β (resp. 0.81 (p b 0.001), 7.80
(p b 0.001) and 0.29 (p = 0.046)). The additional decline of
IL-10 is without the use of the interaction with age. There was
no significant evidence for an association between IL-8
genotype and a more severe lung disease.3.2. Cross-sectional data
A total of 130 CF children, 69 females (53.1%), between
9.50 and 10.48 years of age were recruited (mean: 9.94 years).
A total of 106 patients (81.5%) had at least one ΔF508 allele.
Thirty-nine patients had PA infection (32%), 2 patients (1.5%
Table 2
Descriptive longitudinal data.
(N = 152)
Sex
Male/female 71 (46%)/81 (53%)
Total FEV1 measurements 10,956
FEV1 measurements
Mean per year 5.5
FEV1 % predicted
Mean (range) 68.3 (13–146)
TNF-α genotype
Non-inflammatory 100 (66%)
Pro-inflammatory 52 (34%)
IL-8 genotype
Non-inflammatory 44 (29%)
Pro-inflammatory 107 (71%)
IL-10 genotype
Non-inflammatory 45 (30%)
Pro-inflammatory 106 (70%)
IL-1β genotype
Non-inflammatory 69 (45%)
Pro-inflammatory 83 (54%)
Table 4
Additional yearly decline with pro-inflammatory allele.
Pro-inflammatory allele Yearly decline of FEV1% predicted p-Value
All patients (N = 152)
TNF-α genotype a 1.05 0.005
IL-8 genotype −1.15 b0.001
IL-10 genotype −0.24 0.049
IL-1β genotype −0.41 b0.001
Deceased patients (n = 9)
TNF-α genotype b – –
IL-8 genotype −3.38 0.016
IL-10 genotype 2.42 b0.001
IL-1β genotype 0.93 0.005
Living patients (n = 143)
TNF-α genotype a −1.28 0.001
IL-8 genotype −1.32 b0.001
IL-10 genotype −0.35 0.004
IL-1β genotype −0.54 b0.001
a Regression without interaction of age.
b Deceased patients with any TNF-α pro-inflammatory allele n = 0.
703L. de Vries et al. / Journal of Cystic Fibrosis 13 (2014) 699–705of all patients) were positive for the clonal PA strain and BC
was found in 5 patients (3.8%) (Table 5).
Table 6 displays the adjusted difference between the normal and
abnormal cytokine genotype groups for each outcome and cytokine,
95% CI and p-value. There was no evidence of an association
between the cytokine genotypes and the clinical outcomes.Table 5
Descriptive data: cross-sectional data.
N = 130
Age (years)
Mean (range) 9.94 (9.5–10.5)
Sex
Male/female 61 (47%)/69 (53%)
PA positive 39 (32%)
Clonal PA strain 2 (1.5%)
BC positive 5 (3.8%)
CF genotype (df 508)
Homozygote 66 (51%)
Heterozygote 40 (31%)
Nil 9 (7%)
Unknown 15 (12%)
TNF-α genotype
Non-inflammatory 86 (66%)
Pro-inflammatory 44 (34%)
IL-8 genotype
Non-inflammatory 36 (28%)
Pro-inflammatory 93 (72%)
IL-10 genotype
Non-inflammatory 42 (33%)
Pro-inflammatory 87 (67%)4. Discussion
Ascertaining candidate modifier genes contributing to clinical
phenotypes in CF is challenging and complex due to the likely
multifactorial genetic and environmental influences. To increase
the likelihood of finding SNPs which are relevant to the severity
of lung disease in cystic fibrosis we performed a longitudinal
study as well as a cross-sectional study to examine the effect of
gene variability in four cytokine genes (TNF-α, IL-8, IL-10 and
IL-1β) on clinical outcomes. In the cross-sectional part of this
study we adjusted for some of the multifactorial influences. To
improve statistical power we included a large number of lung
function measurements over an extended period. We found an
association between three of the four cytokine genotypes (IL-8,
IL-10 and IL-1β) and FEV1 by looking at all patients over a
13 year period. A lesser decline in lung function with any
pro-inflammatory allele of IL-10 and IL-1β, when looking at the
deceased patients only, may be a spurious association because of
the small number of patients (n = 9), testing of multiple alleles orTable 3
Cytokine genotype groupings.
Cytokine Group 1 Group 2
TNF-α GG AG or AA
IL-8 TT AT or AA
IL-10 GG AG or AA
IL-1β CC CT or TT
Group 1 — no “pro-inflammatory” allele.
Group 2 — any “pro-inflammatory” allele.a lower baseline of the FEV1 percent predicted in the group of
deceased patients.
We found no association between any of the cytokine
genotypes analysed and FEV1 or BMI z-score at the age of ten
years, while adjusting for the multifactorial influences.IL-1β genotype
Non-inflammatory 59 (45%)
Pro-inflammatory 71 (55%)
BMI
Mean 16.44
BMI z-score
Mean (sd) −0.26 (0.82%)
Best FEV1 % pred
Mean (range) 86.94 (46–132)
PA: N = 122.
IL-8: n = 129 and IL-10: n = 129.
Table 6
Association between cytokine polymorphisms and clinical outcomes.
Adjusted differences
(polymorphic-common)
95% CI p-Value
FEV1 % predicted
TNF-α −0.05 (−6.87, 6.76) 0.99
IL-8 3.12 (−4.29, 10.54) 0.41
IL-10 −3.02 (−10.01, 3.89) 0.39
IL-1β −5.40 (−12.01, 1.20) 0.11
BMI z-score
TNF-α −0.07 (−0.73, 0.59) 0.83
IL-8 0.35 (−0.36, 1.07) 0.33
IL-10 −0.30 (−0.98, 0.37) 0.37
IL-1β −0.48 (−1.12, 0.16) 0.14
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severe lung disease is similar to that found by Miller et al. [20].
Analysis of a patient population of 737 patients homozygous
for ΔF508 CFTR mutation showed a significant genotypic
association of IL-8 and TGF-1β with CF lung disease severity
(Pb or =0.05). Dorfman described a weak association with the
variants in the IL-8 gene and more severe lung function in CF,
but the relationship was not associated with the risk of sporadic
or chronic infections [14,22].
In contrast to other studies we found a significant association
between IL-10 and IL-1β and a more severe lung disease
[4,7,21]. Where we found a lesser decline in lung function for
patients with any pro-inflammatory allele of TNF-α, some
studies have reported a more rapid deterioration in lung function
whereas other studies found no association [4,7,9,11,12].
There are several limitations to our study. Although we
found significant differences in the lung function between
patients with pro-inflammatory and non-inflammatory cytokine
alleles in the longitudinal data analyses, this does not explain a
large proportion of the variation of the FEV1 % predicted as age
accounts for the majority of the variation (adj. R-squared age =
0.12, adj. R-squared age ∗ IL-8 = 0.13, p b 0.001). Secondly,
by showing a relationship between pro-inflammatory gene
polymorphisms and severity of CF pulmonary disease it is
recommended to adjust for genetic and environmental influ-
ences. A study by Tesse showed evidence of a higher risk of
chronic pulmonary infection with PA for carriers of the high
IL-10 producing GCC haplotype [23]. In the longitudinal part
of this study we did not adjust for confounders, such as gender,
BMI and presence of lung infections as this statistical analysis
was not possible with the available data.
Thirdly, other studies have chosen patients with similar CF
genotypes, such as only those homozygous forΔF508, whereas in
the cross-sectional part of our study we chose to adjust for CF
genotype by regression so as not to lose the power of that part of
the study [4]. Our longitudinal cohort included 81 patients (53.3%)
who are homozygous for the ΔF508 gene. This small number
limits our ability to make conclusions regarding associations
between the cytokine genotype and the severity of lung disease.
Fourthly, it is likely that very large numbers are required to
show a relationship between pro-inflammatory gene polymor-
phisms and severity of CF pulmonary disease. Our cohort forthe cross-sectional part consisted of 130 patients as we had to
exclude 28 patients without any lung function measurements. A
reason for their exclusion could therefore be the fact that at the
time these patients reached the age of 10 an annual lung
function measurement was not standard practice.
Lastly, it may be better to analyse PA acquisition by age at
first isolation, however this may also necessitate differentiating
between those who subsequently clear the organism with
eradication therapy and those that do not. It is also difficult to
obtain this information in younger patients unless regular
broncho-alveolar lavages have been performed.
In summary, we have studied the effect of 4 potential modifier
genes on clinical outcome variables in a cohort of children with
CF.We found an association between polymorphisms of the IL-8
gene (at least one copy of the “A” allele at position −251 in the
promoter region), the IL-10 gene (at least one copy of the “A”
allele at position −1082 in the promoter region) and the IL-1β
gene (at least one copy of the “T” allele at position −511 in the
promoter region) and an additional yearly decline in lung
function over a 13 year period. The cross-sectional data did not
show a significant association between clinical outcomes and the
cytokine genotype. Future longitudinal studies to explore the
mechanisms of the association between SNPs of the IL-8, IL-10
and IL-1β genes and the different confounders as well as
pulmonary disease in CF are indicated.
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